Caliper Life Sciences (CALP) Partners with Prestwick Chemical to Offer Customized Chemistry and Biology Programs for Drug Discovery Research
11/19/2009 11:00:18 AM
More...
|
Biovail Corporation (BVF) Acquires Prestwick Pharmaceuticals, Inc. for $100 Million
9/17/2008 6:52:00 AM
More...
|
Prestwick Pharmaceuticals, Inc.'s XENAZINE(R) Approved by FDA for Patients with Chorea Associated with Huntington's Disease
8/15/2008 2:01:04 PM
More...
|
Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
8/30/2007 6:47:06 AM
More...
|
Prestwick Pharmaceuticals, Inc. Strengthens Management Team with Appointment of Robert S. Radie as Chief Business Officer
8/23/2007 7:59:51 AM
More...
|
Prestwick Pharmaceuticals, Inc.'s Clinical Trial Results Suggest Long-Term Treatment Benefit of Tetrabenazine for Chorea Associated with Huntington's Disease
5/4/2007 3:28:36 AM
More...
|
Prestwick Pharmaceuticals, Inc. Announces Resignation Of Kathleen Clarence-Smith, M.D., Ph.D., As Director, Founder And Chief Research And Development Officer
1/24/2007 11:38:56 AM
More...
|
Prestwick Pharmaceuticals, Inc. Appoints George F. Horner III As President And Chief Executive Officer
8/22/2006 8:07:25 AM
More...
|
Prestwick Pharmaceuticals, Inc. Raises $60 Million In Series C Financing
7/24/2006 10:58:14 AM
More...
|
Prestwick Pharmaceuticals, Inc. Release: Study Published In Neurology Shows Tetrabenazine Significantly Improves Debilitating Movement Disorder Caused By Huntington's Disease
2/14/2006 12:59:28 PM
More...
|
|